Some commentary from Macquarie emailed yesterday, this looks to be a major issue ATM and keeping the share price well below the 4.77 high.
Emerging Leaders
Acrux ACR Underperform
Rebates remain stubbornly high
* Eli Lilly reported Axiron 4Q net sales at US$23.9m (vs. Macq at US$22.6m).
* Solid net sales number due to lower than expected rebate; however, it appears that the rebate has increased on a seasonally adjusted basis.
* Underperform. Positive that Q4 rebates were lower than Q3, but still increased on a seasonally adjusted basis and concern about slowing market growth.
rebate
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
-0.002(4.08%) |
Mkt cap ! $14.24M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.6¢ | $15.47K | 324.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 154451 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 15.17pm 11/11/2024 (20 minute delay) ? |
| ACR (ASX) Chart |